• Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

    14 days ago - By San Diego Biotechnology

    SAN DIEGO--Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use Ligand's full OmniAb antibody......
    Read more ...